Akifumi Kogame

Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist

Nobuyuki Negoro, Shinobu Sasaki, Satoshi Mikami et al. · ACS Medicinal Chemistry Letters · 2010 · 246 citations · Full text

Molecular Pharmacology, Pharmaceutical Science, Selective Gpr40 Agonist +12

Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor

Kenichi Iwai, Tadahiro Nambu, Ryo Dairiki et al. · Science Advances · 2019 · 67 citations · Full text

In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients

Tomotaka Tanaka, Hideharu Okanobu, Shandra K. Yoshimi et al. · Digestive and Liver Disease · 2008 · 62 citations

Inflammation, Autoimmune Disease, Mucosal Immunology +11

A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery

Kenichi Iwai, Tadahiro Nambu, Yukie Kashima et al. · Science Advances · 2021 · 25 citations · Full text

Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa

Jun Matsukawa, Akifumi Kogame, Yoshihiko Tagawa et al. · Digestive Diseases and Sciences · 2016 · 20 citations

Radiographic Localization Study, Gastrointestinal Pharmacology, Medicine +5